Figure 3.

KO islet function is compromised after transplantation into KO diabetic recipients. Numbers of mice (n) per group are indicated. Blood glucose levels are shown in the upper row and % of mice with normoglycemia is shown at the bottom row. Data from different groups were assessed by ANOVA. For percentages of normoglycemic mice in different groups, ANOVA was performed after they were square-rooted, followed by arcsin transformation. P values are reported. (A) KO islets perform poorly after transplantation into KO recipients. A dose-limiting number of KO islets (350 islets/recipient) were transplanted under the renal capsules of syngeneic WT and KO recipients, which were rendered diabetic by prior STZ treatment. Blood glucose levels of the recipients were monitored for 31 days. Blood glucose levels of the different groups and the percentages of mice that reached normoglycemia (<12 mm) are reported. (B) KO and WT donor islets have comparable function in WT recipients. Islets from KO and WT donors were transplanted into WT diabetic recipients; their blood glucose levels and percentages of mice becoming normoglycemic were monitored for 31 days, as described in (A). (C) WT donor islets have comparable function in WT and KO recipients. Islets from WT donors were transplanted into diabetic WT and KO recipients; their blood glucose levels and percentages of mice becoming normoglycemic were monitored for 31 days, as described in A. (D) KO mice are prone to multiple low-dose STZ-induced diabetes. KO and WT male mice were treated i.p. with low dose STZ (40 mg/kg, q.d. for 5 days). Their blood glucose levels and percentages of mice with normoglycemic were monitored once every 3 days from Day 6 until Day 34.